Our Team

Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions. Leveraging $13M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance. The company’s lead assets are at Pre-IND stage and poised for Phase 1 readiness in 2023.

KRIS AALTO, BS

CEO
25 years of bioengineering,
innovation development,
regulatory and clinical affairs,
product launch, VC and
executive experience.

DEB FULLER, PHD

CTO
Co-inventor of MACH-1
technology, formerly at
PowderJect, UW Professor, the
lab focuses on NA vaccines for
multiple pathogens.

KEN BAGLEY, PHD

Director R&D
15 years in NA
vaccine field, developed genetic
adjuvant platform at Profectus
Biosciences, Inc.

HANNAH FRIZZELL, PHD

Program Director, Preclinical Development
Preclinical Development Bioengineer,
Immunology, and nano delivery
system experience.

LYUDA LEBEDINSKI, BS

Senior Administrative and
Financial Manager
Experienced
biomedical research finance,
federal funding and
management professional.

ATHARVA BHALERAO, BS

Research Scientist and Analyst
Preclinical program laboratory
and business development
support.

BECCA TEODOSIU, BS

Biomedical Engineer

Ariana Aalto

Communications and Business Development Intern